United Therapeutics CorporationUTHRNASDAQ
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank28
Year-over-Year Change
Year-over-year free cash flow growth rate
Latest
-50.71%
↓ 211% vs avg
Percentile
P28
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
45.88%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -50.71% |
| Q3 2025 | 171.51% |
| Q2 2025 | -66.48% |
| Q1 2025 | 51.79% |
| Q4 2024 | -15.36% |
| Q3 2024 | 60.72% |
| Q2 2024 | -44.69% |
| Q1 2024 | 369.86% |
| Q4 2023 | -74.33% |
| Q3 2023 | 355.36% |
| Q2 2023 | -81.53% |
| Q1 2023 | 275.99% |
| Q4 2022 | -53.27% |
| Q3 2022 | 72.55% |
| Q2 2022 | -60.03% |
| Q1 2022 | 164.62% |
| Q4 2021 | -35.92% |
| Q3 2021 | 23.05% |
| Q2 2021 | 66.54% |
| Q1 2021 | -30.47% |
| Q4 2020 | -51.55% |
| Q3 2020 | 61.25% |
| Q2 2020 | -27.68% |
| Q1 2020 | 159.13% |
| Q4 2019 | -54.71% |
| Q3 2019 | 52.58% |
| Q2 2019 | 117.26% |
| Q1 2019 | -2041.96% |
| Q4 2018 | -82.86% |
| Q3 2018 | 55.19% |
| Q2 2018 | -46.96% |
| Q1 2018 | 309.60% |
| Q4 2017 | -148.03% |
| Q3 2017 | 374.90% |
| Q2 2017 | -76.86% |
| Q1 2017 | 44.72% |
| Q4 2016 | -32.29% |
| Q3 2016 | 90.46% |
| Q2 2016 | -1.28% |
| Q1 2016 | 2035.06% |